Uzbekistan is the most populous country in Central Asia with 36 million people. The country has the only plant in Central Asia specializing in insulin production for the treatment of diabetes. Uzbek authorities aim to develop 90 pharma projects worth $1.2bn by 2026.
Uzbekistan annually consumes $1.6bn worth of pharmaceutical products. Most of this volume – almost $1.2bn in production – is imported.
Local pharma production leaders are factories such as Jurabek, NIKA Pharm and Nobel. Among the European manufacturers whose drugs are...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
